CORDIS · CCHFVaccine
Crimean-Congo Haemorrhagic Fever Vaccine
- Code
CCHFVaccine- Programme
- H2020
- Call
SC1-PM-06-2016- Status
- CLOSED
- Period
- 2017-01-01 – 2025-09-30
Official data · CORDIS · synced 2026-10-17 10:16 · official record
Participants
| Organisations | Role | Country | Grant |
|---|---|---|---|
| FOLKHALSOMYNDIGHETEN | coordinator | SE | 2 294 000 € |
| KAROLINSKA INSTITUTET | participant | SE | 1 224 076 € |
| FRIEDRICH LOEFFLER INSTITUT - BUNDESFORSCHUNGSINSTITUT FUER TIERGESUNDHEIT | participant | DE | 505 000 € |
| INSERM TRANSFERT SA | participant | FR | 401 875 € |
| JUSTUS-LIEBIG-UNIVERSITAET GIESSEN | participant | DE | 348 281 € |
| Department of Health | participant | UK | 348 000 € |
| STATENS VETERINAERMEDICINSKA ANSTALT | participant | SE | 227 750 € |
| SIVAS CUMHURIYET UNIVERSITESI | participant | TR | 140 250 € |
| BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL | participant | DE | 136 000 € |
| KAFKAS UNIVERSITESI | participant | TR | 134 375 € |
| НАЦИОНАЛЕН ЦЕНТЬР ПО ЗАРАЗНИ И ПАРАЗИТНИ БОЛЕСТИ | participant | BG | 80 000 € |
| TAJIK RESEARCH INSTITUTE OF PREVENTIVE MEDICINE | participant | TJ | 80 000 € |
| MINISTRIA E SHENDETESISE | participant | XK | 60 000 € |
| REGION STOCKHOLM | third party | SE | 0 € |
Description
Natural epidemics and outbreaks of emerging viral epidemics are growing problems internationally. The general aim of the CCHFVaccine project is to develop and deliver a vaccine, which can significantly increase our capacity to control the situation of Crimean Congo Haemorrhagic fever (CCHF) disease on a global basis. The proposed work program on CCHF virus aims to build a multidisciplinary research network, able to deliver vaccine candidates, methods and procedures eligible for clinical trials, with a special focus on prevention. Thanks to the background, unique facilities and tools available among the consortium participants, CCHFVaccine will deliver tools for countering the threat of this infection in Europe and endemic areas of the world. This work program will attempt to fill gaps in CCHFV virus research on immunology and vaccinology. To achieve this overall aim, an intensive work plan will be put in place with the following specific objectives: i) to produce vaccine candidates, ii) to bring several unique animal models into front line vaccine research, iii) to validate and bring the most promising vaccine candidates to clinical trials, iv) to ensure that an immune mediated protection is adequately understood, v) to perform clinical trials at Phase I and ensure a strategy for the effective deployment and utilization in resource-poor countries, and vi) to link this project to public health bodies, NGOs and vaccine companies. The proposed CCHFVaccine project will succeed in bringing together selected competitive advantages such as: operating capacity with appropriate facilities (state-of-the-art BSL-4s) and the only animal BSL-4 -with capacity to challenge domestic animals in Europe, highly experienced researchers in the development and evaluation of vaccine candidates, authorities and entities of human and animal health, clinical samples from endemic countries, and an international network proven to be functional by the previous EU-funded CCHFever and EDENext.
Official data · CORDIS · synced 2026-10-17 10:16 · official record · Licence: © European Union, CC BY 4.0 (Commission reuse policy).